Here are the 10-K annual reports from GeoVax Labs, Inc. Warrants (GOVXW) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow GOVXW and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full GOVXW filings page.
GeoVax Labs, Inc. is a clinical-stage biotech developing vaccines and immunotherapies for infectious diseases and solid tumors, built mainly on its Modified Vaccinia Ankara (MVA) platform and the Gedeptin gene-directed cancer therapy.
The company’s lead near-term program is GEO-MVA, an mpox/smallpox vaccine being advanced on an expedited European regulatory pathway, with a pivotal Phase 3 immuno-bridging trial planned for the second half of 2026. Oncology candidate Gedeptin completed a multicenter Phase 1/2 head and neck cancer trial and is being prepared for a Phase 2 study in combination with an immune checkpoint inhibitor, targeted to start in the first half of 2027.
COVID-19 vaccine GEO-CM04S1 is in multiple Phase 2 trials in immunocompromised patients and as a booster; an interim review in a CLL study supported continued enrollment in the investigational arm after the mRNA control failed its primary immune endpoint. A BARDA-backed Phase 2b effort under Project NextGen was later terminated for convenience, after GeoVax had met all milestones.
The company reported a $21.5 million net loss for 2025 and research and development expenses of $18.1 million, and its auditors issued a going concern opinion. GeoVax states its existing cash is expected to fund operations into the middle of the second quarter of 2026, and it highlights a need for substantial additional capital to continue advancing its pipeline.